Clinical Trials

88 enrolled

Liver Neoplasms

NCT06040099 2026-03-19

EMERALD-Y90

58 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT05806931 2026-03-18

SCOTI

50 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT07071714 2026-03-18

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

200 enrolled

Colorectal Neoplasms

NCT05528952 2026-03-16

TERTIO

105 enrolled

Carcinoma, Hepatocellular

NCT07474727 2026-03-16

A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

180 enrolled

Colorectal Neoplasms

NCT06607458 2026-03-13

DEL-LIVER

90 enrolled

Rectal Neoplasms, Colorectal Neoplasms

NCT07011550 2026-03-11

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

Phase 2 Suspended

7 enrolled

Microsatellite-stable Colorectal Cancer

NCT06096779 2026-03-06

Kirros

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT04563338 2026-03-05

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

36 enrolled

Carcinoma, Hepatocellular

NCT04721132 2026-03-05

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

16 enrolled

Carcinoma, Hepatocellular

NCT07446322 2026-03-04

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

60 enrolled

Ras-mutated Metastatic Colorectal Cancer

NCT05775159 2026-02-18

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

294 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT02519348 2026-02-17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 enrolled 26 charts

Carcinoma, Hepatocellular

NCT07323576 2026-02-09

INAVO-CRC

Phase 2 Withdrawn

Colorectal Neoplasms

NCT03937830 2026-02-05

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

27 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

34 enrolled

Colorectal Neoplasms

NCT06268015 2026-02-05

BBOpCo

16 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06679985 2026-02-05

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

72 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT05733611 2026-02-02

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 2 Terminated

5 enrolled

Colorectal Neoplasms

NCT07359456 2026-01-22

COLIBRI-GI

130 enrolled

Colorectal Neoplasms

NCT06948448 2026-01-21

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

144 enrolled

Colorectal Neoplasms

NCT07005570 2026-01-21

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

86 enrolled

pMMR/MSS Locally Advanced Rectal Cancer

NCT06792695 2026-01-20

CANTOR

120 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT07347951 2026-01-16

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Rectal Neoplasms

NCT07337551 2026-01-13

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

20 enrolled

Colorectal Neoplasms

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

113 enrolled

Colorectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Colorectal Neoplasms

NCT06332079 2026-01-05

HAITI

Phase 2 Terminated

4 enrolled

Colorectal Cancer Metastatic

NCT07317414 2026-01-05

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

158 enrolled

Carcinoma, Hepatocellular

NCT06540326 2025-12-22

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

100 enrolled

Colorectal Cancer Metastatic

NCT05733598 2025-12-15

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

60 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT07179900 2025-12-11

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

60 enrolled

Carcinoma, Hepatocellular

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT05843188 2025-12-09

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

155 enrolled

Colorectal Neoplasms

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07253896 2025-11-28

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

40 enrolled

Colorectal Neoplasms

NCT07239245 2025-11-25

ATTACH

Carcinoma, Hepatocellular

NCT01191697 2025-11-03

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Phase 2 Completed

37 enrolled 11 charts

Esophageal Neoplasms, Stomach Neoplasms

NCT05620771 2025-10-20

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Phase 2 Suspended

84 enrolled

Carcinoma, Hepatocellular

NCT06789757 2025-10-07

(HCC)

19 enrolled

Carcinoma, Hepatocellular

NCT05377034 2025-10-06

STRATUM

100 enrolled

Carcinoma, Hepatocellular

NCT06784947 2025-10-02

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

13 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02982694 2025-10-01

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Phase 2 Terminated

46 enrolled

Colorectal Neoplasms, Activated Protein C Resistance

NCT04727307 2025-09-30

AB-LATE02

202 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT04595266 2025-09-29

LIVERPEARL

48 enrolled

Colorectal Neoplasms

NCT07150247 2025-09-26

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

20 enrolled